These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10138581)

  • 41. Controlling moxalactam and cefotaxime use with a target drug program.
    Abramowitz PW; Ludwig DJ; Mansur JM; Nold EG
    Hosp Pharm; 1983 Aug; 18(8):416-20. PubMed ID: 10261791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of a clinical pharmacist-enforced intensive care unit sedation protocol on duration of mechanical ventilation and hospital stay.
    Marshall J; Finn CA; Theodore AC
    Crit Care Med; 2008 Feb; 36(2):427-33. PubMed ID: 18091554
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Economic impact of pharmacist's interventions: illustration in a rheumatology ward].
    Coursier S; Bontemps H; Brantus JF; Allenet B
    J Pharm Belg; 2008 Dec; 63(4):103-9. PubMed ID: 19320133
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks.
    Nakayama H; Echizen H; Tanaka M; Sato M; Orii T
    Ther Drug Monit; 2008 Feb; 30(1):103-7. PubMed ID: 18223471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
    Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
    J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.
    Caspi D; Lubart E; Graff E; Habot B; Yaron M; Segal R
    Arthritis Rheum; 2000 Jan; 43(1):103-8. PubMed ID: 10643705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding.
    Tsoi KK; Lau JY; Sung JJ
    Gastrointest Endosc; 2008 Jun; 67(7):1056-63. PubMed ID: 18407271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Documentation of clinical interactions: quality of care issues and economic considerations in critical care pharmacy.
    Bearce WC; Willey GA; Fox RL; Coleman LT
    Hosp Pharm; 1988 Oct; 23(10):883-4, 886, 889-90. PubMed ID: 10290109
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Educational effort and CQI program improves ordering of serum digoxin levels.
    Wade WE; McCall CY
    Hosp Formul; 1994 Sep; 29(9):657-9. PubMed ID: 10137062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and cost effectiveness of new antiemetic guidelines.
    Engstrom C; Hernandez I; Haywood J; Lilenbaum R
    Oncol Nurs Forum; 1999 Oct; 26(9):1453-8. PubMed ID: 11064877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.
    Clay PG; Graham MR; Lindsey CC; Lamp KC; Freeman C; Glaros A
    Am J Geriatr Pharmacother; 2004 Sep; 2(3):181-9. PubMed ID: 15561650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and economic benefits of a clinical pharmacokinetic service: 1987 versus 1992 data.
    Destache CJ
    Med Interface; 1994 Nov; 7(11):84-6, 89-90. PubMed ID: 10138706
    [No Abstract]   [Full Text] [Related]  

  • 54. Justification of a pharmacy intravenous admixture service in an Australian hospital.
    Plumridge RJ; Maher M
    Am J Hosp Pharm; 1993 Mar; 50(3):463-6. PubMed ID: 8442462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Audit of ranitidine administration in parenteral nutrient solutions.
    Hershey AG; Rosen GH; Foster MD; Johnson DS; Martir-Herrero ML; Krieger J; Oh SM
    Am J Hosp Pharm; 1991 Jan; 48(1):104-7. PubMed ID: 1900386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Movement of the i.v. room to the postanesthesia care area: an alternative to an operating room satellite pharmacy.
    Martin WR
    Hosp Pharm; 1992 Apr; 27(4):323, 327-8, 330-1 passim. PubMed ID: 10117771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Converting intravenous cimetidine and ranitidine therapy to oral therapy.
    Oh T; Rumsey K; Neistein J; Francko TG
    Am J Hosp Pharm; 1988 Jul; 45(7):1497. PubMed ID: 3414712
    [No Abstract]   [Full Text] [Related]  

  • 58. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
    Falbe WJ; Bess DT; Capers CC; Haymond JD; Stahl AA
    Am J Hosp Pharm; 1992 Mar; 49(3):632-3. PubMed ID: 1598944
    [No Abstract]   [Full Text] [Related]  

  • 59. Cost comparison of oral, nasogastric, and intramuscular cimetidine drug delivery systems.
    Lau NC; Caldwell RD; Arford PH
    Hosp Pharm; 1992 Nov; 27(11):946-7, 950-2, 954-6 passim. PubMed ID: 10122039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral ranitidine as prophylaxis for gastric stress ulcers in intensive care unit patients: serum concentrations and cost comparisons.
    Pemberton LB; Schaefer N; Goehring L; Gaddis M; Arrighi DA
    Crit Care Med; 1993 Mar; 21(3):339-42. PubMed ID: 8440101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.